InnoCare, Zenas, Orelabrutinib: $2 B Licensing Deal Fuels MS Therapeutic Pipeline
InnoCare Pharma Limited (HKG: 9969) announced a landmark exclusive license and subscription agreement with Zenas...
Zenas BioPharma
Zenas Secures $300 M Royalty Deal for Obexelimab – Royalty Pharma to Invest
Zenas BioPharma, Inc. (NASDAQ: ZBIO) and Royalty Pharma, Inc. (NASDAQ: RPRX) announced a milestone partnership...
Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases
US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation...
Zenas BioPharma Completes $118M Series B Financing to Advance Obexelimab
Autoimmune disease drug developer Zenas BioPharma, which is based in the US and China, has...